Does This Valuation Of Everest Medicines Limited (HKG:1952) Imply Investors Are Overpaying?
Key Insights The projected fair value for Everest Medicines is HK$20.13 based on 2 Stage Free Cash Flow to Equity Everest Medicines is estimated to be 22% overvalued based on current share price of
Everest Medicines' Loss Widens in 2023
Everest Medicines' (HKG:1952) net loss attributable to equity holders widened to 844.5 million yuan in the year ended Dec. 31, 2023, from a loss of 247.3 million yuan a year ago, according to a Wednes
雲頂新耀-B:2023年度報告
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 8%, and many positive results of Nifukang appeared in WCN2024
Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
[Broker Focus] Western Securities maintains Genting Xinyao (01952) holdings” rating indicates that several catalysts will soon be implemented this year
According to the Western Securities Research Report, Genting Xinyao (01952) made many advances in drug registration and commercialization in 2023. Driven by new product sales, the company's revenue increased dramatically in 2023. Eiga and Nifukang achieved sales of 99 million yuan and 21 million yuan respectively. If non-cash projects are not included, the company's gross margin exceeds 80%, and the company's innovative layout is gradually entering the harvest period.
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 6% in the intraday period and surged more than 20% this week, and the IgA nephropathy market reappeared with 10 billion acquisitions
Genting Xinyao B (01952) rose more than 6% in the intraday period, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Everest Medicines Limited (HKG:1952) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Everest Medicines Limited (HKG:1952) shareholders are probably feeling a little disappointed, since its shares fell 3.7% to HK$23.50 in the week after its latest full-year results. Revenue great
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 5% after the performance, annual revenue increased nearly 9 times, and many executives announced a voluntary ban on sales
Genting Xinyao B (01952) rose more than 5% after the results. As of press release, it had risen 5.02% to HK$23, with a turnover of HK$58,3951 million.
Genting Xinyao-B (01952) announced 2023 results and achieved revenue of 126 million yuan, an increase of 884% year-on-year
Genting Xinyao B (01952) announced its 2023 results, with revenue of RMB 126 million, an increase of 884%; R&D expenditure of approximately RMB 540 million, a decrease of 33.3% year over year; and net loss of approximately RMB 844.5 million.
EVEREST MED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Changes in Hong Kong stocks | Genting Xinyao B (01952) is now up more than 6%. The company has appointed a chief medical officer and chief product officer, and many management have promised to voluntarily ban sales
The Zhitong Finance App learned that Genting Xinyao B (01952) is now up more than 6%. As of press release, it has risen 5.47% to HK$27, with a turnover of HK$139 million. According to the news, Genting Xinyao announced that in the important stage of implementing “independent development and successful commercialization of products based on mRNA platforms” two-wheel drive, the company appointed Ms. Zeng Qingwen as Chief Medical Officer and Mr. Liang Xu as Chief Product Officer to further strengthen the management team and enhance strategic integration between R&D, clinical development, medical affairs and marketing departments. In addition, CBC Group, the controlling shareholder of Genting Xinyao, is an executive director of the company
Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercial
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
Genting Xinyao B (01952.HK): Controlling Shareholder and Certain Senior Management Commitments to Ban Sales Voluntary Sales
Gelonghui, March 18 | Genting Xinyao B (01952.HK) issued an announcement. The controlling shareholder of the company, CBC Group, Luo Yongqing, the company's executive director and CEO, and He Ying, the company's executive director and chief financial officer, have notified the company that they each voluntarily promised not to sell any shares in the company directly or indirectly owned by them for at least six months, based on firm confidence in the company's future prospects and long-term development.
Everest Medicines Limited's (HKG:1952) Last Week's 10% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
Key Insights The considerable ownership by retail investors in Everest Medicines indicates that they collectively have a greater say in management and business strategy 51% of the business is held b
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon
SHANGHAI, March 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Callidit
Genting Xinyao will announce 2023 annual results on March 28, 2024
A biopharmaceutical company focusing on the development, manufacture and commercialization of innovative drugs and vaccines announced today that the company will announce its 2023 annual results and business progress on March 28, 2024, Beijing time, and hold an online performance conference in English and Chinese on the same day.
Genting Xinyao B (01952.HK) plans to hold a board meeting on March 27 to approve annual results
Gelonghui March 6 | Genting Xinyao B (01952.HK) issued an announcement. The board of directors is pleased to hold a board meeting on March 27, 2024 (Wednesday) to consider and approve the Group's annual results for the year ended December 31, 2023, and to deal with other matters.
EVEREST MED-B: DATE OF BOARD MEETING
No Data